These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

625 related items for PubMed ID: 16311734

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 5. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH, Zhang C, Zhang X, Gao L, Gao L, Kong PY, Peng XG, Qi DG, Sun AH, Zeng DF, Liu H, Gong Y, Wang QY.
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [Abstract] [Full Text] [Related]

  • 6. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA, Faul C, Bornhäuser M, Stuhler G, Beelen DW, Lang P, Stelljes M, Vogel W, Hägele M, Handgretinger R, Kanz L.
    Blood Cells Mol Dis; 2008 Feb; 40(1):13-9. PubMed ID: 17869547
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Non-CD34+ cells, especially CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation.
    Kim DH, Won DI, Lee NY, Sohn SK, Suh JS, Lee KB.
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):719-28. PubMed ID: 16785061
    [Abstract] [Full Text] [Related]

  • 9. Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies.
    Chang YJ, Zhao XY, Huang XJ.
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):323-34. PubMed ID: 18275899
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease.
    Huang XJ, Han W, Xu LP, Chen YH, Liu DH, Lu J, Chen H, Zhang YC, Jiang Q, Liu KY, Lu DP.
    Chin Med J (Engl); 2004 Dec; 117(12):1778-85. PubMed ID: 15603704
    [Abstract] [Full Text] [Related]

  • 12. Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors.
    Zhao XY, Chang YJ, Xu LP, Liu DH, Liu KY, Huang XJ.
    Bone Marrow Transplant; 2009 Dec; 44(11):721-8. PubMed ID: 19377516
    [Abstract] [Full Text] [Related]

  • 13. Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics.
    Porta MD, Rigolin GM, Alessandrino EP, Maiocchi M, Malcovati L, Vanelli L, Baratè C, Rumi E, Ciccone M, Cuneo A, Lazzarino M, Castoldi G.
    Eur J Haematol; 2004 Jan; 72(1):18-25. PubMed ID: 14962258
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
    Dhédin N, Chamakhi I, Perreault C, Roy DC, Sauvageau G, Ducruet T, Busque L, Fish D, Bélanger R, Roy J.
    Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397
    [Abstract] [Full Text] [Related]

  • 17. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study.
    Joshi SS, Bishop MR, Lynch JC, Tarantolo SR, Abhyankar S, Bierman PJ, Vose JM, Geller RB, McGuirk J, Foran J, Bociek RG, Hadi A, Day SD, Armitage JO, Kessinger A, Pavletic ZS.
    Cytotherapy; 2003 Jan; 5(6):542-52. PubMed ID: 14660050
    [Abstract] [Full Text] [Related]

  • 18. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity.
    Bethge WA, Haegele M, Faul C, Lang P, Schumm M, Bornhauser M, Handgretinger R, Kanz L.
    Exp Hematol; 2006 Dec; 34(12):1746-52. PubMed ID: 17157172
    [Abstract] [Full Text] [Related]

  • 19. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S.
    Blood Cells Mol Dis; 2008 Dec; 40(1):48-54. PubMed ID: 17827036
    [Abstract] [Full Text] [Related]

  • 20. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia.
    Mavroudis DA, Read EJ, Molldrem J, Raptis A, Plante M, Carter CS, Phang S, Dunbar CE, Barrett AJ.
    Bone Marrow Transplant; 1998 Mar; 21(5):431-40. PubMed ID: 9535034
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.